Considerations and practical implications of performing a phenotypic CRISPR/Cas survival screen.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35176052.
- Also identified by DOI 10.1371/journal.pone.0263262 and PMC identifier 8853573.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Genome-wide screens that have viability as a readout have been instrumental to identify essential genes. The development of gene knockout screens with the use of CRISPR-Cas has provided a more sensitive method to identify these genes. Here, we performed an exhaustive genome-wide CRISPR/Cas9 phenotypic rescue screen to identify modulators of cytotoxicity induced by the pioneer transcription factor, DUX4. Misexpression of DUX4 due to a failure in epigenetic repressive mechanisms underlies facioscapulohumeral muscular dystrophy (FHSD), a complex muscle disorder that thus far remains untreatable. As the name implies, FSHD generally starts in the muscles of the face and shoulder girdle. Our CRISPR/Cas9 screen revealed no key effectors other than DUX4 itself that could modulate DUX4 cytotoxicity, suggesting that treatment efforts in FSHD should be directed towards direct modulation of DUX4 itself. Our screen did however reveal some rare and unexpected genomic events, that had an important impact on the interpretation of our data. Our findings may provide important considerations for planning future CRISPR/Cas9 phenotypic survival screens.
Medical subject headings
- CRISPR-Cas Systems
- Gene Expression Regulation
- Homeodomain Proteins
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Muscle Cells
- Muscular Dystrophy, Facioscapulohumeral
- Myoblasts